Pages that link to "Q33984489"
Jump to navigation
Jump to search
The following pages link to Clinical trials of antibody therapy (Q33984489):
Displaying 50 items.
- Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding (Q24291716) (← links)
- Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation (Q24806498) (← links)
- Engineering a protein scaffold from a PHD finger (Q27641617) (← links)
- Elicitation of structure-specific antibodies by epitope scaffolds (Q27664711) (← links)
- Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies (Q27690917) (← links)
- Improving the efficacy of antibody-based cancer therapies (Q28208361) (← links)
- Antibodies on demand: a fast method for the production of human scFvs with minimal amounts of antigen (Q28743142) (← links)
- Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells (Q30489241) (← links)
- Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy (Q30790872) (← links)
- Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity (Q30835165) (← links)
- Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. (Q31016741) (← links)
- n-CoDeR concept: unique types of antibodies for diagnostic use and therapy (Q31043274) (← links)
- Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. (Q31067966) (← links)
- Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity (Q31135653) (← links)
- Phage library panning against cytosolic fraction of cells using quantitative dot blotting assay: application of selected VH to histochemistry (Q32063798) (← links)
- Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro and in vivo (Q33184127) (← links)
- Generation of high-affinity fully human anti-interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast (Q33662280) (← links)
- Design, synthesis, and biological evaluation of a biyouyanagin compound library (Q33796299) (← links)
- Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies (Q34102657) (← links)
- New approaches in the treatment of asthma. (Q34192933) (← links)
- The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity (Q34232543) (← links)
- Monoclonal antibody strategies to block angiogenesis (Q34258670) (← links)
- Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice (Q34276582) (← links)
- Therapeutic antibody gene transfer: an active approach to passive immunity (Q34344211) (← links)
- Functional heavy-chain antibodies in Camelidae (Q34419540) (← links)
- Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells (Q34431577) (← links)
- Human therapeutic antibodies (Q34441137) (← links)
- Papillomavirus-like particle based vaccines: cervical cancer and beyond (Q34451862) (← links)
- Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody (Q34526792) (← links)
- Chemokines: agents for the immunotherapy of cancer? (Q34576416) (← links)
- Inflammation and the development of pancreatic cancer (Q34646491) (← links)
- Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? (Q34700652) (← links)
- Cloning of B cell-specific membrane tetraspanning molecule BTS possessing B cell proliferation-inhibitory function (Q34703754) (← links)
- Anti-CD20-based therapy of B cell lymphoma: state of the art. (Q34926739) (← links)
- New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies (Q34990105) (← links)
- Neutralizing antibodies in gene-defective hosts (Q35053404) (← links)
- Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases (Q35090142) (← links)
- Redirecting T lymphocyte specificity using T cell receptor genes (Q35126976) (← links)
- Renaissance of cancer therapeutic antibodies (Q35159047) (← links)
- Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis (Q35208773) (← links)
- Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases (Q35581131) (← links)
- Costimulation-based immunotherapy for head and neck cancer (Q35617137) (← links)
- Vectored antibody gene delivery for the prevention or treatment of HIV infection (Q35664155) (← links)
- Anti-cytokine Ab immune therapy: present status and perspectives (Q35687684) (← links)
- Medical applications of leukocyte surface molecules--the CD molecules (Q35690889) (← links)
- Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody (Q35918866) (← links)
- Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer (Q36066311) (← links)
- FLT3 antibody-based therapeutics for leukemia therapy (Q36251188) (← links)
- Potent antibody therapeutics by design (Q36452621) (← links)
- Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines (Q36536313) (← links)